Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2025-03-25 Capital/Financing Update
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득 (제6회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing regarding the acquisition of convertible bonds before maturity by the issuer (AdBiotech). It details the specific series (6th), the amount acquired, the reason for acquisition (redemption request due to loss of benefit of time), and the source of funds. This falls under capital structure changes and financing updates, specifically related to debt instruments.
2025-03-25 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the fiscal year ending December 31, 2024, for Addbiotech Co., Ltd. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. While it contains financial data, it is primarily the formal audit report issued by an accounting firm, which falls under the 'Audit Report / Information' category. FY 2024
2025-03-21 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) submitted to the Korea Exchange (KRX). It contains key financial data, audit opinions (적정), and financial statements for the fiscal year. While it provides financial summaries, it is a standard regulatory disclosure form used in the Korean market to announce the completion and submission of the audit report, rather than the full, multi-page annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2024
2025-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This is a standard regulatory filing used to disclose insider trading or changes in share ownership by company executives. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2025-03-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific executive (Jung Eun-jeong) at AdBiotech. This type of filing is a standard regulatory requirement for insider trading or changes in executive share ownership, which corresponds to the 'Director's Dealing' category.
2025-03-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). This document details changes in share ownership by major shareholders and special related parties, including acquisition methods like market purchases and capital increases. It is a formal disclosure of significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2025-03-18 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.